GIGABYTE
3.1.2022 07:05:09 CET | Business Wire | Press release
GIGABYTE is joining CES Virtual with its website extension – INDUSTRY – to present products and solutions that propel digital transformation in industries such as 5G & telecom, automotive, creative & gaming, data centers , manufacturing, and retail.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005431/en/
GIGABYTE takes pride in having an incredibly deep portfolio of enterprise products that support cloud, edge, and data centers. There are over 75 servers for AMD EPYC CPU alone, as well as Intel Xeon Scalable CPU, and over 10 servers for Ampere Altra CPU, and not to forget over 20 server motherboards. GIGABYTE offers edge servers developed based on Arm architecture. These high-density Arm servers , using Ampere’s massive 80 / 128 core CPU, provide the performance, storage, network, and above all, the flexibility to be deployed for the next generation of telecommunications where processing work needs to be done on-site. GIGABYTE’s server solutions are also applicable to various industries, and are highly valued by large and small high-tech companies, medical, scientific, academic research, and public institutions, etc., and have successfully assisted them in innovation and breakthroughs in their fields.
Our industries are undergoing an invigorating metamorphosis as AI, HPC, IoT, and other breakthroughs bring about a paradigm shift. MyelinTek Inc., an investee company of GIGABYTE developed a deep learning system MLSteam, which includes optimized AI software stacking and comprehensive management tools in a user-friendly interface to make it easier for scientists to train and develop AI integration for autonomous vehicles. With the rapid development of Advanced Driver Assistance Systems (ADAS ) technology, GIGABYTE designs decision-making control units for different types of autonomous vehicles, as well as customized products such as ADAS ECUs, TCUs, assisting vehicles designers to develop their ideal products and improve the automotive industry.
GIGABYTE has years of proven experience in embedded computers and brought its latest generation of embedded systems to increase the operability of storage, logistic, and manufacturing facilities while lowering labor and management costs with the innovation of AGV, AMR, and Industrial Automation Security System. In the post-pandemic era, GIGABYTE’s embedded solutions integrated with AI and IoT technology helped automate the operation and management of open space rentals, allowing such new services to flourish.
GIGABYTE’s reputation to invent top-notch products with innovative VRM and thermal design makes the task to optimize overclocking performance on the latest Intel® Core™ CPUs easy and effective. The Z690 series motherboards provide beyond the essential features and power for both professional creators and gamers alike. Performance is the key to both immersive gameplay and smooth workflow, and GIGABYTE has taken performance above all else with this generation’s AORUS gaming laptops and the AERO creator laptops which are to be released in early 2022.
GIGABYTE has recently launched INDUSTRY to demonstrate its most pivotal products and solutions for different industries. One of the biggest highlights of the platform is its live chat function. GIGABYTE has arranged experts, who have keen insights on the industries, to standby the live chat and answer questions and inquiries made by CES visitors and buyers as they would at the physical venue. The live chat uses AI-generated avatars to show the status of its live experts, and also as a way to embrace the ‘metaverse ’ where virtual merges with reality. The INDUSTRY platform will host all products and solutions GIGABYTE is presenting at CES including trendy topics highlighted in the event and more. GIGABYTE welcomes all visitors to connect through this digital platform and see their industries from different perspectives.
INDUSTRY: https://industry.gigabyte.com
Visit GIGABYTE on CES Digital: https://gbte.tech/ces2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005431/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom